Romiplostim
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Romiplostim
- Romiplostim: From Chronic Immune Thrombocytopenia to Primary Release Disorder of Platelets
Romiplostim: From Chronic Immune Thrombocytopenia to Primary Release Disorder of Platelets
One-Sentence Summary
Romiplostim is a thrombopoietin receptor agonist (TPO-RA) originally developed for chronic immune thrombocytopenia (ITP). The TxGNN model predicts it may be effective for Primary Release Disorder of Platelets, currently supported by 1 clinical trial (indirect, non-interventional) and 2 publications (mechanistic/review only).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic immune thrombocytopenia (ITP) — based on known drug information; no Danish license record exists since the product is not yet marketed |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 99.9998% |
| Evidence Level | L3 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on known information, romiplostim is a thrombopoietin receptor agonist (TPO-RA) — an Fc-peptide fusion protein that binds and activates the TPO receptor (MPL) on megakaryocytes, stimulating their proliferation and maturation to increase platelet production. Its efficacy in chronic ITP, where autoantibody-mediated platelet destruction and impaired thrombopoiesis reduce circulating platelet counts, has been well established.
“Primary release disorder of platelets” describes conditions in which platelet production or release from megakaryocytes is deficient. Mechanistically, this overlaps directly with romiplostim’s mode of action, since stimulating megakaryocytopoiesis and thrombopoiesis is expected to increase platelet output regardless of the specific upstream cause of the release defect.
The supporting literature (PMID 23594368, 25682608) describes megakaryocyte and proplatelet-formation biology, including how ITP autoantibodies impair proplatelet formation — reinforcing the biological plausibility of the mechanism-based link. However, none of the current evidence tests romiplostim directly in patients with a primary platelet release disorder; the single clinical trial identified is an observational ITP thrombosis-risk registry, not an interventional romiplostim trial.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03820960 | N/A | Completed | 10,039 | Observational registry on risk factors for thrombosis in immune thrombocytopenia (ITP); does not directly test romiplostim, provides disease-population background only (relevance grade C) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23594368 | 2013 | Review | British Journal of Haematology | Overview of megakaryocytopoiesis and thrombopoiesis, describing thrombopoietin (TPO) as the primary growth factor driving platelet production |
| 25682608 | 2015 | Basic/Mechanistic | Haematologica | Shows antiplatelet autoantibodies in ITP inhibit proplatelet formation by megakaryocytes, impairing platelet production in vitro |
Denmark Market Information
Romiplostim is not currently marketed in Denmark — no national (Laegemiddelstyrelsen) or centralised (EMA) marketing authorisation is on record in this Evidence Pack (0 authorisations).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The current evidence base is mechanistic/observational only (L3) — no interventional trial or clinical case series has tested romiplostim specifically in patients with a primary platelet release disorder, and the drug is not marketed in Denmark, with a blocking data gap on TFDA/SmPC warnings and contraindications.
To proceed, the following is needed:
- Approved SmPC/label data (warnings, contraindications, drug interactions)
- Confirmed mechanism of action (MOA) documentation from DrugBank or equivalent
- Direct interventional evidence (case series or trial) of romiplostim in patients with primary platelet release disorders
- Confirmation of EU/Danish regulatory pathway or marketing authorisation status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.